INSUBCONTINENT EXCLUSIVE:
to the company's injectable formulation manufacturing facility at Pashamylaram, Hyderabad.
The Unit IV of the facility was inspected by
USFDA from November 4 to November 13
scrip from falling 8.9 per cent to Rs 394.70
This was the lowest level for the scrip since October 7.
The drugmaker reported a 4.6 per cent rise in its consolidated net profit at Rs
639.5 crore for the quarter ended September 30, 2019.
The company had posted a net profit of Rs 611.4 crore in the corresponding period in
previous fiscal, Aurobindo Pharma said in a BSE filing.
Aurobindo Pharma's revenue increased 17.9 per cent to Rs 5,600.5 crore during the
equity share of Re 1 for the year 2019-20.
"We had another quarter of healthy performance where we continued to grow in US and Europe, which
are our focused geographies," Aurobindo Pharma Managing Director N Govindarajan said.
He added that the company's R-D initiatives have
been progressing well across the products basket.